Published in Support Care Cancer on November 14, 2006
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer (2013) 1.21
Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer (2012) 1.20
Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer (2010) 1.16
Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer (2008) 1.16
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer (2013) 1.12
Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol (2013) 1.10
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer (2008) 1.05
Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits (2012) 1.05
Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer (2014) 0.99
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist (2015) 0.97
Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer (2010) 0.96
Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer (2010) 0.94
Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer (2014) 0.92
How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer (2008) 0.89
Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial. Springerplus (2014) 0.88
Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer (2012) 0.86
Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med (2011) 0.84
Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Support Care Cancer (2015) 0.83
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther (2014) 0.83
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer (2016) 0.83
Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol (2010) 0.82
Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy. Arch Drug Inf (2008) 0.81
Can ginger ameliorate chemotherapy-induced nausea? Protocol of a randomized double blind, placebo-controlled trial. BMC Complement Altern Med (2014) 0.81
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. Cancer Manag Res (2014) 0.81
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer (2009) 0.81
Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res (2013) 0.81
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer (2016) 0.80
Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). Support Care Cancer (2012) 0.79
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int (2015) 0.79
Effect of virtual reality on time perception in patients receiving chemotherapy. Support Care Cancer (2010) 0.79
Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits (2014) 0.79
Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimens. Oncol Lett (2014) 0.79
Gastrointestinal symptom representation in cancer symptom clusters: a synthesis of the literature. Oncol Nurs Forum (2012) 0.79
Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study. Support Care Cancer (2015) 0.79
Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. BMC Health Serv Res (2014) 0.79
Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice. Support Care Cancer (2011) 0.78
Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer (2014) 0.78
Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives. Cancer Manag Res (2016) 0.78
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy. Cancer Manag Res (2009) 0.78
Hindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea. Physiol Behav (2015) 0.77
Association between serotonin transport polymorphisms and postdischarge nausea and vomiting in women following breast cancer surgery. Oncol Nurs Forum (2014) 0.77
An investigation of the effects of therapeutic touch plan on acute chemotherapy-induced nausea in women with breast cancer in Isfahan, Iran, 2012-2013. J Educ Health Promot (2015) 0.77
An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context (2015) 0.77
The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study. Support Care Cancer (2011) 0.77
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. Am Health Drug Benefits (2015) 0.77
Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis. Support Care Cancer (2016) 0.77
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. Support Care Cancer (2009) 0.75
The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting. J Adv Pract Oncol (2016) 0.75
Excitatory Hindbrain-Forebrain Communication Is Required for Cisplatin-Induced Anorexia and Weight Loss. J Neurosci (2017) 0.75
Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. Toxicol Res (2012) 0.75
Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. Breast Cancer Res Treat (2016) 0.75
Supportive care in hemato-oncology: a review in light of the latest guidelines. Turk J Haematol (2012) 0.75
Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. Medicine (Baltimore) (2016) 0.75
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer (2016) 0.75
Chemotherapy-induced nausea and vomiting: exploring patients' subjective experience. J Multidiscip Healthc (2016) 0.75
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. Support Care Cancer (2017) 0.75
Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia. Mol Clin Oncol (2017) 0.75
A Scientific Rationale to Improve Resistance Training Prescription in Exercise Oncology. Sports Med (2017) 0.75
Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.75
Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting. Support Care Cancer (2016) 0.75
Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol (1984) 3.76
Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer (2004) 3.04
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol (1997) 2.96
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med (1990) 2.15
On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol (1996) 2.03
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol (1985) 1.72
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med (1990) 1.29
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1997) 1.29
Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol (1989) 1.18
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol (1991) 1.10
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol (1994) 1.05
Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol (1996) 0.99
Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer (1992) 0.92
Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum (2003) 0.89
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Cancer (1992) 0.88
The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer (1990) 0.86
NCCN antiemesis practice guidelines. Oncology (Williston Park) (1997) 0.80
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol (1992) 0.78
Effective control of cisplatin-induced nausea using high-dose steroids and droperidol. Cancer Treat Rep (1982) 0.78
Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research. Ann Oncol (1994) 0.78
A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol (1996) 0.78
Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer (1991) 0.77
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.89
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA (2002) 2.58
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol (2009) 2.48
Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol (2012) 1.36
The effects of smoking deprivation and nicotine administration on emotional reactivity. Nicotine Tob Res (2006) 1.25
The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf (2006) 1.20
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res (2013) 1.02
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest (2002) 0.96
Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. Psychosom Med (2006) 0.95
LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm (2007) 0.93
Predicting initiation of smoking in adolescents: evidence for integrating the stages of change and susceptibility to smoking constructs. Addict Behav (2002) 0.90
Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol (2010) 0.89
Skin cancer prevention counseling and clinical practices of pediatricians. Pediatr Dermatol (2003) 0.86
Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf (2012) 0.86
Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. Pharmacoepidemiol Drug Saf (2009) 0.85
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Vasc Health Risk Manag (2013) 0.82
Migraine strikes study: factors in patients' decision to treat early. J Headache Pain (2009) 0.75
Thermal conductivities of nanostructured magnesium oxide coatings deposited on magnesium alloys by plasma electrolytic oxidation. J Nanosci Nanotechnol (2014) 0.75
Cost analysis of five antimicrobial regimens for the treatment of intra-abdominal infection. Surg Infect (Larchmt) (2008) 0.75
Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf (2006) 0.75